Izalontamab

Multispecific antibody

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

No completed mid-stage readout is on record. The registry's posted readout date (2026-07) has passed without a status update. Check News for topline announcements.

Also in development:Head and Neck Squamous Cell Carcinoma · Phase 2Esophageal Squamous Cell Carcinoma · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Non-Small Cell Lung Cancer
Phase 2/3 (1)
Non-Small Cell Lung Cancer
Phase 2 (6)
Esophageal Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
NCT05044897 · Sichuan Baili Pharmaceutical Co., Ltd.
2021-10-20 – 2025-12 · Head and Neck Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT05020457 · Sichuan Baili Pharmaceutical Co., Ltd.
2021-12-07 – 2025-12 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05039944 · Sichuan Baili Pharmaceutical Co., Ltd.
2021-11-30 – 2022-06-06 · Colorectal Cancer
What this study did
Phase 1/2 (2)
Head and Neck Squamous Cell Carcinoma
NCT05668858 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-02-10 – 2027-12 · Squamous Cell Carcinoma of Head and Neck
What this study did
Non-Small Cell Lung Cancer
NCT05949606 · Sichuan Baili Pharmaceutical Co., Ltd.
2023-10-30 – 2027-12 · Non-small Cell Lung Cancer
What this study did
Phase 1 (1)
Other / comorbidity
NCT04603287 · Sichuan Baili Pharmaceutical Co., Ltd.
2020-04-17 – 2025-12 · Locally Advanced or Metastatic Epithelial Tumor
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Esophageal Squamous Cell Carcinoma: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Izalontamab: this drugPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT03189719: Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590).
NCT02564263: Overall survival, pembrolizumab vs investigator's-choice chemotherapy: HR 0.70 (95% CI 0.52 to 0.94) in PD-L1 CPS >=10, HR 0.77 (0.63 to 0.96) in ESCC, HR 0.89 (0.75 to 1.05) in all randomized patients; the label approval is for ESCC with CPS >=10 (KEYTRUDA label, KEYNOTE-181).
TislelizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT03957590: Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months missed
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Izalontamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-11 · NCT06668961 · CT.gov ↗
What to watch
December 2026 (3)
Phase 1/2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT05668858 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT05949606 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT05054439 · CT.gov ↗
What to watch

See the full readout calendar ↗